IDH wild-type

P=N/A, N=50, Recruiting, Ottawa Hospital Research Institute | Trial completion date: May 2031 --> Nov 2031 | Trial primary completion date: Nov 2026 --> May 2027

The patient was treated with temozolomide concurrently with radiotherapy, followed by tumor treating fields with adjuvant temozolomide...Various tyrosine kinase inhibitors, including entrectinib, larotrectinib, repotrectinib, and selitrectinib, along with bevacizumab, were considered to potentially prolong progression-free survival and overall survival and improve quality of life. We expect to highlight the rarity of this case while discussing the effectiveness of second-generation tyrosine kinase inhibitors in high-grade glioblastomas with rare gene fusions. We also hope to identify the appropriate timeline and treatment sequence for post-standard care, given the lack of official guidelines regarding cases this infrequent.

These findings suggest that a subset of morphologically defined cerebellar glioblastomas in adults represents the dpHGG, H3-/IDH-WT, RTK1 subtype. Recognition of this underappreciated manifestation is important for accurate tumor classification, and further accumulation of well-characterized cases is required to clarify its clinical significance.

Several alterations associated with cystic GBM, including CDK4 and KDR, are targets of small-molecule inhibitors. Further research is required to explore the diagnostic and therapeutic implications of this association.

We retrospectively analyzed 20 patients with newly diagnosed primary IDH-wildtype glioblastoma who underwent gross-total resection followed by standard radiotherapy and temozolomide treatment between 2016 and 2022...However, given the limited sample size, the selection of extreme survival groups, and the predominance of chromosomal polysomy detected by FISH, these findings should be interpreted as hypothesis-generating only. Further validation in larger cohorts using high-resolution genomic methods is warranted.

Overall, these data describe subtype-specific patterns of m6A marking and isoform architecture across glioma tissues, derived from computational inference using direct RNA sequencing in a modestly sized cohort and warrant validation by orthogonal methods in larger studies. These findings are consistent with concurrent independent evidence that isoform-specific m6A deposition is evolutionarily conserved across mammals and that long-read isoform resolution reveals transcript diversity in glioma not captured by gene-level analysis. While cohort size and the absence of orthogonal site-level validation suggest that the data require cautious interpretation, this work provides a hypothesis-generating resource and methodological framework for future mechanistic and translational investigation of the glioma epitranscriptome.

Tumors originating in occipital lobe had highest propensity to migrate to new sites (57.1%) and the shortest time to progression (adjusted HR = 1.90, p = 0.026). These findings support molecular-demographic-anatomical risk stratification that may inform personalized margin-determination in radiotherapy planning.

P1, N=30, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Jun 2026 --> Dec 2026

MRI characteristics provide a promising non-invasive tool for predicting TERTpm status, whereas MGMTm serves as an independent prognostic marker for glioblastomas. These findings provide new insights for the early diagnosis of glioblastomas.

Despite ongoing challenges in cost, data interpretation, and large-scale integration, single-cell epigenomics has potential applications in refining glioblastoma classification and guiding personalized therapeutic strategies in the future. This review explores emerging roles of DNA methylation in glioblastoma alongside cutting-edge single-cell techniques and translational prospects.

P=N/A, N=228, Recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Not yet recruiting --> Recruiting | Trial completion date: Oct 2028 --> May 2031 | Trial primary completion date: Apr 2027 --> May 2028

P1, N=30, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting